Role of Sentinel Lymph Node Biopsy for Skin Cancer Based on Clinical Studies

Abstract

The sentinel lymph node is the first lymph node from the primary tumor. Sentinel lymph node biopsy (SLNB) is a surgical procedure that can detect occult nodal metastasis with relatively low morbidity. It may also have a therapeutic effect via regional disease control. The Multicenter Selective Lymphadenectomy-I (MSLT-I) trial revealed a prognostic benefit from SLNB in melanoma patients. However, it remains unclear whether there is a prognostic benefit from SLNB in patients with nonmelanoma skin cancer owing to a lack of randomized prospective studies. Nevertheless, SLNB provides important information about nodal status, which is one of the strongest factors to predict prognosis and may guide additional nodal treatment. Currently, SLNB is widely used in the management of not only patients with melanoma but also those with nonmelanoma skin cancer. However, the utilization and outcomes of SLNB differ among skin cancers. In addition, SLNB is not recommended for routine use in all patients with skin cancer. In this review, we provide a summary of the role of SLNB and of the indications for SLNB in each skin cancer based on previously published articles.

Dedifferentiated endometrial carcinoma metastasis to axillary lymph node: a case report

“…In total, 97% of axillary LN mets originate from the breast [ 22 ]. Other locoregional sites of origin include trunk or upper limb skin lesions, such as melanoma or other skin malignancies, including squamous or Merkel cell carcinomas [ 23 ].…”